← Evidence map

TrialBMC infectious diseases2025

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial.

Aihua Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Immunogenicity and safety of a booster dose of the COVID-19 DNA vaccine in healthy adults aged 18 years and above: a single-center, randomized, observer-blind, placebo-controlled phase 2 trial. | Socratic